Iranian company produces nanodrug for cancer diagnosis

An Iranian knowledge-based company has developed a novel technique for cancer diagnosis with the production of the advanced nanodrug, Tilmanocept. 

The technique is now available for 90 percent of the Iranian patients. 

According to the information center of the office of the Iranian the Vice President for Science, Technology, and Knowledge-Based Economy, this achievement positions Iran among the leading countries in medical technology and cancer diagnosis. 

Tilmanocept, produced by Aprin Sama PharMed Company, boosts the accuracy of cancer detection while significantly reducing costs for patients. 

Accurate identification of lymph node involvement in cancer is crucial, especially when it comes to breast, lung, and genital cancers, as the lymphatic system is the primary pathway for cancer metastasis. 

If affected lymph nodes are not detected in a timely manner, surgeons may need to remove extensive parts of the lymphatic system, which would lead to numerous side effects that can severely impact patients’ immune systems and blood circulation. 

Tilmanocept allows for precise detection of cancerous lymph nodes through injection and scanning, helping prevent unnecessary surgeries and their associated complications. 

Previously, this sophisticated radiopharmaceutical was exclusively produced by the US.